19^th Global Biomarkers and Clinical Research Summit August 22-23, 2023 Paris, France

Growth research is fundamental research into tumor to recognize causes and create methodologies for aversion, analysis, treatment and cure. Growth investigations range from the study of disease transmission, sub-atomic bioscience to the execution of clinical trials to assess and think about utilizations of the different malignancy medicines. These applications incorporate surgery, radiation treatment, chemotherapy, hormone treatment, and immunotherapy and consolidated treatment modalities, for example, chemo-radiotherapy. Beginning in the mid-1990s, the accentuation in clinical diseases explorations moved towards treatments derived from biotechnology research, for example, tumor immunotherapy and quality treatment.

Neurological Biomarkers is a branch of medicine that deals with the diagnosis of nervous system, central nervous system, autonomic nervous system and Peripheral nervous system including their coverings, tissues, blood vessels and neurons. In the discipline of Neurology, personalized medicine has been recently becoming an important part of clinical practice. Neurology has a play a main role in personalized medicine and diagnostic, prognostic as well as predictive under neurological disorders. Such neurological disorders are Stroke, Multiple sclerosis, Epilepsy, Parkinson’s disease and Alzheimer’s diseases.

Biomarkers in Neuro-oncology Brain tumor & Brain damage

Biomarkers for early identification of Neurological disorders

Biomarkers in central nervous system diseases

Personalized medicine and diagnostic in Neuro science

Cerebrospinal fluid biomarkers

There is a neglected requirement for approved biomarkers particular to immunotherapies that would control treatment choices particular to every patient, by maintaining a strategic distance from choice of ineffectual treatments and toxicities and counteracting components of safe getaway. It has turned out to be progressively obvious that the standards utilized for the advancement of biomarkers for customary focused on treatment may not matter to malignancy immunotherapy. The essential obstacle constraining exploration endeavors to recognize biomarkers are the unpredictability and dynamic nature of the connections between the resistant framework and tumor cells. Accordingly, understanding the complex pathobiology of cancer– safe framework cooperation’s is vital.

Challenges to biomarkers development in Immune system

Biomarkers discovery in Immunology

Biomarkers for Early Progressive Inflammatory & Immunological Diseases

Biomarkers of Disease Pathogenesis

Biomarkers under autoimmune system

Digital biomarkers says that the objective, quantifiable physiological and behavioral data that are gathered and measured by means of digital devices like portables, wearable, implantables, or digestible. The data collected are typically wont to explain, influence, and/or predict health-related outcomes. Digital biomarkers also represent a chance to capture clinically meaningful, objective data.

Biomarker transform into the foundation of assurance and treatment of any afflictions now a days. Companion tests are normally performed in the midst of clinical examination. There are a settled number of tests (65) are under reimburse order as picked by the Centers for Medicare and Medicaid Service. So the current issues with the reimbursement may influence the entry of new nuclear test in the business areas and need certain alterations in the present game plan.

Circulatory Biomarker

Biomarkers for Heart Failure & Acute Coronary Syndrome

Biomarkers for Metabolic Syndrome & Cardiovascular Risk

Molecular biomarkers are often estimate from the molecules of particular sample  which indicates the  presence of disease or diseased state physiological change response to a treatment or physiological state .It has the collection of techniques to analyses from genomics and proteomics within the individual ordering. These are often performed by the action of applying biology into medical testing

Nucleic acid-based Biomarkers

Proteomic Biomarkers

Genomic Biomarkers

Blood based Biomarker

Small molecule Biomarkers

Lipid Biomarkers

MicroRNA Biomarkers

Transcriptomic Biomarkers

Histological Biomarkers is defined as a biochemical or molecular alteration in cells, tissues or fluids that can be measured and evaluated to indicate normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. Histological Biomarkers have the application of diagnosis and understanding the different levels of anatomical regions such as cell, tissue and organism. In addition, the biomarkers at tissue  level such  as histological alterations in different  organs give valuable information.

Biomarker in cell diagnosis

Protein Phosphorylation Biomarkers

Histopathological Biomarker

Blood and Tissue Biomarker

Stem cell Biomarker

Immune-histological Biomarkers

Cytology has been act as a main tool utilised in the diagnosis of cancer. These techniques have evolved from an era of diagnosis based on haematoxylin and eosin (H&E) stained slides to the current regular evaluation of tumours by immunocytochemistry (IHC) to confirm tumour histogenesis and subtype. In breast cancer, this means the routine IHC evaluation of hormone receptors (oestrogen and progesterone receptors) as well as evaluation of HER2 expression and Ki67 (a marker of tumour proliferation). These factors strongly influence prognosis and the selection of anti-cancer treatments.

Cytological carcinoma

Cytopathology marker

A Cancer biomarker alludes to a substance or process that has the characteristic of the nearness of malignancy in the body. A biomarker might be a molecule discharged by a tumor or a particular reaction of the body to the nearness of disease. Hereditary, epigenetic, proteomic, glycomic, and other biomarkers can be utilized for malignant growth finding, guess, and the study of disease transmission. In a perfect world, such biomarkers can be measured in non-intrusively gathered biofluids like blood or serum

In Cancer research, Biomarkers can be used in 3 important ways:

1. To help analyze conditions, as on account of distinguishing beginning time malignant growths (Diagnostic)\

2. To figure how forceful a condition is, as on account of deciding a patient's capacity to passage without treatment (Prognostic)

3. To anticipate how well a patient will react to treatment (Predictive)

Imaging biomarkers are the classes of biomarkers which allow earlier detection of disease compared to molecular biomarkers, which is streamline translational research in the drug discovery and researchers under cancer images in marketplace. Some of the image-based biomarkers are X-Ray, Computed Tomography (CT), Positron Emission Tomography (PET), Single Photo Emission Computed Tomography (SPECT) and Magnetic Resonance Imaging (MRI).

Imaging Technologies in Clinical Translation

Imaging Strategies and Molecular Profiling in Oncology

Imaging Techniques in Tissue Engineering

Imaging of Internal tissues and organs

Imaging in Neuroscience

Imaging biomarkers in Cardiovascular Systems and Musculoskeletal System

Current genomics and biotechnology promise the development of biomarkers to a state to predict individual disease risk which enable early detection of disease and improve diagnostic classification to better inform individualized treatment. Biomarkers are biological measurements which can be used to predict risk of diseases, to enable early detection of disease, to improve treatment selection and to monitor the outcome of therapeutic interventions. The major objective of the Human Genome Project was the identification and development of such biomarkers for ‘personalized, preventive and predictive medicine’.

The part of Biomarkers in medication revelation and advancement is to comprehend the pathophysiology of ailment. Biomarkers can be a clinical instrument for medication disclosure and improvement by affirming the adequacy and security to the correct patient. Biomarkers can be utilized as a part of comprehension about the instrument of medication.

The Biomarkers discover its important application in the field of clinical innovative work by contextual investigation and information administration as obvious through Biomarker meetings. The Bioethics and protected innovation right builds up the standards and standard of direct of theory concerning clinical approval of biomarkers. The fusion of biomarker in clinical trials for several health disorder conditions will advance a legitimate indicative and remedial approach using even the medicinal gadgets to recognize clinical biomarkers. Right now this is a blasting business. A large portion of the presumed associations like Pfizer, Parexel and Quintiles are into clinical innovative work. The organizations, doctor's facilities and clinical research associations are the problem areas for directing clinical research with its development rate expanding exponentially by an expected 75B$ by 2016.In clinical innovative work, clinical biomarkers are utilized as a part of contextual analysis and information administration, clinical trials and in therapeutic gadgets.

Biomarkers are used for detecting kidney toxicity. Kidney toxicity is detected using biomarkers serum creatinine and blood urea nitrogen. Many qualified biomarkers are used to develop products to conquer the kidney toxicity problem. Latest research on biomarkers discovered new approaches to predicting and recognizing toxic exposures of macromolecular adducts and their potential consequences.

In spite of all the advances in neurology, there are serious deficiencies in our understanding of the path mechanism of several neurological disorders as well as our ability to diagnose and treat these disorders. Biotechnologies are being increasingly applied in neurology to address some of these deficiencies. Novel biomarker identification for neurological disorders will address the current shortcomings in their diagnosis and therapeutics.

A cancer biomarker refers to a substance or process that is indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to presence of cancer. Genetic, epigenetic, proteomic, glycolic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. While some cancer biomarkers can be used to predict how aggressively your cancer will grow, and are therefore useful for assessing your prognosis, the most promising use of biomarkers today is to identify which therapies a patient’s cancer may or may not respond to.

A nutritional biomarker can be any biological specimen that is an indicator of nutritional status with respect to intake or metabolism of dietary constituents. It can be a biochemical, functional or clinical index of status of an essential nutrient or other dietary constituent. Nutritional biomarkers may be interpreted more broadly as a biologic consequence of dietary intake or dietary patterns.

Immune Oncology biomarkers that can be used to identify inflamed tumors that may help to predict a pre-existing antitumor immune response. To identify the Immuno Oncology biomarkers, clarify this unique interplay between the immune system and the tumor, BMS biomarker research is concentrated on 4 types of areas. They are tumor antigens, inflamed tumor markers, immune suppression markers, and host environment factors. Immuno-Oncology (I-O) biomarkers seek to characterize the relationship between the immune system, the tumor and its microenvironment, and the host. A unique interaction of these factors, as well as Immuno Oncology biomarker presence and prevalence, contributes to the balance of activation versus suppression of the antitumor immune response.

Biomarkers in immune monitoring

Mutation analysis using Biomarkers to guide therapies

Cell proliferation Biomarkers

Predictive Biomarkers to immunotherapies

Biomarkers in Companion Diagnostics

Prognostic Biomarkers

Liquid Biopsy for Immuno-Oncology

Tumor Neoantigens as Biomarker and target identification

Biomarkers for combinational immunotherapies

Evaluation of Biomarkers in clinical trials

Role of Biomarkers in Cancer Vaccines development

Tumor Microenvironment profiling

Biomarkers for precision immune-oncology

Tumor markers in cancer care

Biomarkers focusing on two major areas of investigation: the early detection and prognosis. Early diagnosis and Prognostic Research encompasses the research addressing studies on the evaluation of medical tests, markers, prediction models and decision tools. Early diagnosis of cancer generally increases the chances for successful treatment by focusing on detecting symptomatic patients as early as possible. Delays in accessing cancer care are common with late-stage presentation, particularly in lower resource settings and vulnerable populations. The consequences of delayed or inaccessible cancer care are lower likelihood of survival, greater morbidity of treatment and higher costs of care, resulting in avoidable deaths and disability from cancer. Early diagnosis improves cancer outcomes by providing care at the earliest possible stage and is therefore an important public health strategy in all settings.

In clinical trials using imaging, biomarkers and response criteria are used to assess the tumor evolution with therapy. Imaging biomarkers are often root contributors to a clinical trial’s endpoints, but they are not the same. Diagnostic tests and the biological biomarker (biomarkers) they measure are often classified based on the circumstances under which they are used. Biomarkers provide information about a patient at virtually every stage of care. They can help doctors evaluate the likelihood that a patient will develop a disease, diagnose a disorder, evaluate the severity of a disorder and/or its likely progression, determine optimal treatment strategies and monitor response to treatment.

A case report is an elaborate report of the symptoms, signs, disease diagnosis, treatment, and follow-up of an individual patient usually recorded in medical field. Case reports might comprehend a demographic profile of the patient, but typically mention any unusual or unique occurrences. In this conference case reports on biomarker diagnostics, drug discovery and imaging are discussed in detail with relevance to molecular and cancer biomarkers. Cancer biomarkers conferences are a big platform to study case reports of these in precision.

One imperative part of Pathology in the assessment of bosom malignancy is biomarker testing, particularly the precise appraisal of the estrogen receptor (ER), progesterone receptor (PR), and Her2 status of a patient's bosom tumor. Biomarkers can be prognostic, prescient, or both. Prognostic biomarkers are free measures of forecast to such an extent that the nearness or nonappearance of the biomarker is connected with a patient's general clinical result (i.e., danger of repeat and mortality).

Cardiovascular disease (CVD) remains the leading cause of death globally. The identification of traditional risk factors such as age, hypercholesterolemia, hypertension, diabetes mellitus, and smoking has improved primary prevention of CVD. Cardiac markers are measured biomarkers to assess cardiac function. They are often discussed in the context of myocardial infarction, but other conditions can lead to an elevation in the level of the cardiac marker. Cardiac biomarkers are elements that are released into the blood when the heart is damaged or strained. A cardiac marker is used in the identification and risk stratification of patients with chest pain and suspected acute coronary syndrome (ACS). These markers include enzymes, hormones and proteins. Cardiac biomarkers have evolved as essential tools in cardiology in the last 50 years, that is, for primary and secondary prevention, the diagnosis and treatment of acute myocardial infarction (AMI), and the diagnosis and stratification of the risk of heart failure.

In spite of the fact that, there are several helpful impacts of focused medications treating different malignant growths and different sicknesses are promising still there is impediment in their clinical achievement. The elements restricting the clinical achievement incorporate both essential and procured tranquilize opposition including erratic reactions. Henceforth there are different investigates are in advancement to find new Biomarkers for different infection beginning from immune system issue to cardiovascular and Cancers. Immunologic treatment has risen as a critical treatment alternative for some kinds of malignant growths, in light of showings of exceptional adequacy.

Emerging therapeutic biomarkers in Cancers: Endometrial Cancer, Ovarian cancer, Melanoma, Non-small cell lung cancer, Endometrial Carcinoma, Lung Cancer etc.

Emerging Biomarkers in various diseases: Autoimmune hepatitis, Alzheimer’s disease, Renal Damage, Lymphangioleiomyomatosis, HDL Cholesterol, Cardiovascular Diseases, Necrotizing Methicillin‐Resistant Staphylococcus aureus Pneumonia, systemic sclerosis

Emerging Biomarkers for personalized immunotherapies

Current Research Concepts in Biomarkers include research in glucose disorders, Biomarkers in disease and health, technologies in biomarker discovery, translational biomarker research and the use of biomarkers in pre-clinical and clinical studies.

Drug formulation also covers the surrogate end points in the use of biomarkers and patient selection or companion diagnostics and provides insights into clinical biomarker discovery and biomarker development or validation with regulatory implications. Biomarker use can improve pharmaceutical development efficiency by helping to select patients most appropriate for treatment using a given mechanism, optimize dose selection, and provide earlier confidence in accelerating or discontinuing compounds in clinical development.

Biomarker in Drug discovery

Biomarker in Drug Design

Dose selection in Biomarker

Biomarkers of Toxicity & Pharmacology

Biomarkers in dose selection

Evaluation of dose respons